stoxline Quote Chart Rank Option Currency Glossary
  
Immuneering Corporation (IMRX)
6.5  0.08 (1.25%)    02-23 09:31
Open: 6.47
High: 6.5
Volume: 1,446
  
Pre. Close: 6.42
Low: 6.47
Market Cap: 190(M)
Technical analysis
2024-02-23 9:16:08 AM
Short term     
Mid term     
Targets 6-month :  8.46 1-year :  9.89
Resists First :  7.25 Second :  8.46
Pivot price 6.23
Supports First :  6 Second :  5.23
MAs MA(5) :  6.61 MA(20) :  6.24
MA(100) :  6.53 MA(250) :  8.07
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  66.9 D(3) :  74.2
RSI RSI(14): 50.7
52-week High :  14.28 Low :  4.51
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ IMRX ] has closed below upper band by 38.9%. Bollinger Bands are 22.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.68 - 6.72 6.72 - 6.75
Low: 6.2 - 6.25 6.25 - 6.29
Close: 6.35 - 6.43 6.43 - 6.48
Company Description

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Headline News

Wed, 21 Feb 2024
Objective long/short (IMRX) Report - Stock Traders Daily.com

Tue, 20 Feb 2024
FDA fast tracks Immuneering's pancreatic cancer drug By Investing.com - Investing.com

Tue, 20 Feb 2024
Immuneering Corporation (IMRX) Granted FDA Fast Track Designation for IMM-1-104 - StreetInsider.com

Tue, 20 Feb 2024
Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer - Marketscreener.com

Thu, 01 Feb 2024
Immuneering's (IMRX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat

Tue, 09 Jan 2024
With 37% ownership, Immuneering Corporation (NASDAQ:IMRX) has piqued the interest of institutional investors - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -31 (M)
Shares Float 0 (M)
Held by Insiders 2.927e+007 (%)
Held by Institutions 1.438e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.87
Profit Margin 0 %
Operating Margin -12 %
Return on Assets (ttm) 328 %
Return on Equity (ttm) 771 %
Qtrly Rev. Growth -45.8 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -5.576e+007 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -3.46
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 2.67e+006
Forward Dividend 2.63e+006
Dividend Yield 41588800%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android